REG - Nuformix PLC - NXP004 patent application filing

NuformixAnnouncement

12/11/2021 07:05

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211112:nRSL1492Sa&default-theme=true

RNS Number : 1492S  Nuformix PLC  12 November 2021

 

The information communicated within this announcement is deemed to constitute
inside information as stipulated under the Market Abuse Regulations (EU) No.
596/2014. Upon the publication of this announcement, this inside information
is now considered to be in the public domain.

Nuformix plc

("Nuformix" or the "Company")

 

NXP004 patent application filing

 

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet
medical needs in fibrosis and oncology via drug repurposing, announces that it
has filed a new patent application in relation to NXP004.

 

This filing covers a new family of co-crystalline forms of an undisclosed
marketed drug that is approved globally for the treatment of several cancers
and that had global sales of over £1bn in 2020. This is the second patent
application related to NXP004 that Nuformix has filed and it complements the
previous patent application on NXP004 co-crystals, thus expanding the
Company's intellectual property portfolio.

 

Anne Brindley, Chief Executive Officer, Nuformix, commented: "We are pleased
to have filed this new patent application for NXP004. Data that we have
generated on these new co-crystal forms in the past six months has shown
improvements over the marketed form that justifies filing this new
application. This application, if granted, will strengthen the patent estate
for NXP004 and Nuformix's IP portfolio as a whole."

 

Enquiries:

 

 Nuformix plc                                         via Walbrook
 Dr Alastair Riddell, Non-Executive Chairman
 Dr Anne Brindley, CEO

 Allenby Capital Limited                              +44 (0) 20 3328 5656
 Nick Athanas / George Payne (Corporate Finance)
 Stefano Aquilino / Matt Butlin (Sales and Corporate Broking)

 Walbrook PR       nuformix@walbrookpr.com or +44 (0)20 7933 8780
 Anna Dunphy / Phillip Marriage      Tel: +44 (0)7876 741 001 / +44 (0)7867 984 082

 

About Nuformix

Nuformix is a pharmaceutical development company targeting unmet medical needs
in fibrosis and oncology via drug repurposing. The Company aims to use its
expertise in discovering, developing and patenting novel drug forms, with
improved physical properties, to develop new products in new indications that
are, importantly, differentiated from the original (by way of dosage, delivery
route or presentation), thus creating new and attractive commercial
opportunities. Nuformix has an early-stage pipeline of preclinical and Phase
1-ready assets with potential for significant value and early licensing
opportunities.

 

For more information, please visit www.nuformix.com (http://www.nuformix.com/)
.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFLFLDLTLLLIL